Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:ARTVOTCMKTS:CUBTOTCMKTS:SEOVF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.16-0.9%$1.29$0.85▼$4.40$37.30M0.2531,309 shs29,569 shsARTVArtiva Biotherapeutics$1.47-6.4%$2.03$1.47▼$17.31$35.81MN/A181,176 shs2.39 million shsCUBTCurative Biotechnology$0.01$0.01$0.00▼$0.03$9.93M0.36120,684 shs54,820 shsSEOVFSernova Biotherapeutics$0.12$0.14$0.10▼$0.29$39.56M1.085,886 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+2.67%-10.84%-3.89%-57.07%ARTVArtiva Biotherapeutics0.00%-6.96%-25.00%-51.00%+146,999,900.00%CUBTCurative Biotechnology0.00%-2.00%-10.91%-25.19%-40.24%SEOVFSernova Biotherapeutics0.00%+1.43%-7.35%+13.95%-50.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari Therapeutics1.6307 of 5 stars0.05.00.00.02.23.30.0ARTVArtiva Biotherapeutics2.6838 of 5 stars3.50.00.00.02.11.71.3CUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AARTVArtiva Biotherapeutics 3.00Buy$17.801,110.88% UpsideCUBTCurative Biotechnology 0.00N/AN/AN/ASEOVFSernova Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CUBT, SEOVF, ARTV, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.004/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/AARTVArtiva Biotherapeutics$250K143.24N/AN/A$7.68 per share0.19CUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.03) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-213.59%-65.60%8/18/2025 (Estimated)ARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)CUBTCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ASEOVFSernova Biotherapeutics-$23.65M-$0.04N/A∞N/AN/AN/A-396.49%9/15/2025 (Estimated)Latest CUBT, SEOVF, ARTV, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q2 2025SEOVFSernova BiotherapeuticsN/A-$0.01N/A-$0.01N/AN/A5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.160.16ARTVArtiva BiotherapeuticsN/A13.9313.93CUBTCurative BiotechnologyN/AN/AN/ASEOVFSernova BiotherapeuticsN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%ARTVArtiva BiotherapeuticsN/ACUBTCurative BiotechnologyN/ASEOVFSernova BiotherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%ARTVArtiva Biotherapeutics21.40%CUBTCurative BiotechnologyN/ASEOVFSernova BiotherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million19.92 millionNot OptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/ACUBTCurative BiotechnologyN/A1.01 billionN/ANot OptionableSEOVFSernova BiotherapeuticsN/A328.48 millionN/ANot OptionableCUBT, SEOVF, ARTV, and AKTX HeadlinesRecent News About These CompaniesSernova Biotherapeutics Taps CEO to Be Interim ChairJune 2, 2025 | marketwatch.comSernova Appoints Jonathan Rigby as Interim ChairJune 2, 2025 | globenewswire.comChair of Sernova Biotherapeutics ResignsMay 25, 2025 | globenewswire.comSernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 DiabetesMay 22, 2025 | globenewswire.comSernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 DiabetesMay 14, 2025 | globenewswire.comSernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development PlansApril 17, 2025 | globenewswire.comSernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the MedApril 15, 2025 | globenewswire.comSernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 DiabetesApril 1, 2025 | globenewswire.comSernova names Pericles Calias as CDO and head of R&DMarch 11, 2025 | thepharmaletter.comTSernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&DMarch 10, 2025 | globenewswire.comSernova Biotherapeutics Secures $1 Million Convertible Debt FinancingMarch 5, 2025 | globenewswire.comSernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismMarch 3, 2025 | globenewswire.comSernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismFebruary 3, 2025 | globenewswire.comSernova Corp. Shareholders Approve Key Resolutions at Annual MeetingJanuary 14, 2025 | tipranks.comSernova Advances Diabetes Cure with Strategic InitiativesJanuary 14, 2025 | tipranks.comSernova Financial joins FIA Tech’s Databank NetworkJanuary 13, 2025 | finextra.comFSernova Announces Voting Results from its Annual and Special General Meeting of ShareholdersJanuary 13, 2025 | finance.yahoo.comSernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025December 20, 2024 | globenewswire.comFDA fast tracks type 1 diabetes cell therapy from VertexNovember 9, 2024 | pharmaphorum.comPSernova to Present at the 2024 Cell & Gene Meeting on the MesaOctober 3, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUBT, SEOVF, ARTV, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.16 -0.01 (-0.93%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$1.16 +0.00 (+0.08%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Artiva Biotherapeutics NASDAQ:ARTV$1.47 -0.10 (-6.37%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.47 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Curative Biotechnology OTCMKTS:CUBT$0.0098 0.00 (0.00%) As of 06/27/2025 03:33 PM EasternCurative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.Sernova Biotherapeutics OTCMKTS:SEOVF$0.12 0.00 (0.00%) As of 06/27/2025Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
